When matched with the demonstration of the effects in appropriate models of the living environment of tumors such as patient-derived xenografts, the potential of using anti-CXCL8-CXCR1/2-targeting therapeutics in the clinical management of cancer may become a true and widely exploited reality. The gene discussed is CXCR1; the disease is cancer.